Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types-Reference-Cited by-同舟云学术

Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types

Published:2017-02-11 Issue:25 Volume:8 Page:41590-41604
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Yoon Jae-Ho¹,Kim Hee-Je¹,Park Sung-Soo¹,Jeon Young-Woo¹,Lee Sung-Eun¹,Cho Byung-Sik¹,Eom Ki-Seong¹,Kim Yoo-Jin¹,Lee Seok¹,Min Chang-Ki¹,Cho Seok-Goo¹,Kim Dong-Wook¹,Lee Jong-Wook¹,Min Woo-Sung¹

Affiliation:

1. Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia;Cancers;2023-03-08

2. Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification;Cancers;2022-06-29

3. A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML);Therapeutic Advances in Hematology;2022-01

4. Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study;BLOOD RESEARCH;2021-09-30

5. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients;Transplantation and Cellular Therapy;2021-09